The fertility company quietly assembling the medicine cabinet US patients were never offered.
It is late 2025, and in fertility clinics from one coast to the other, women starting IVF are being offered a study. The drug has a clinical name only a regulator could love - an investigational human menopausal gonadotropin - and behind it sits a company most people have never heard of. Seventeen employees. A pomegranate for a namesake. A pivotal Phase III trial called GRACE.
Granata Bio does not look like a company that should be running a multi-center trial against the biggest names in reproductive medicine. That is rather the point. It has spent seven years doing the unglamorous work the industry skipped: finding fertility medicines that already work somewhere in the world, and walking them through the door marked "United States."
Here is the uncomfortable truth the founders kept bumping into. The global infertility-medication market is worth billions, demand is rising, and yet the toolkit US doctors reach for has barely changed in a generation. Effective therapies exist - they are simply approved elsewhere, stuck behind the cost and patience required to bring a drug to the American market. Big pharma had bigger fish to fry.
So patients did the math no one should have to. They paid out of pocket, traveled, or simply went without. The shortfall was not scientific. It was a question of who would bother to do the work.
Granata Bio's wager is almost stubbornly simple: treat that gap as a business, not a tragedy. In-license what works. Run the trials. Win the approvals. Hand clinicians one more option than they had yesterday.
Evan Sussman spent nine years at EMD Serono, the fertility arm of pharma giant Merck KGaA, ending up as head of the US fertility business. He knew exactly where the gaps were, because he had spent a career standing next to them. In 2018 he co-founded Granata Bio to fill them.
He did not do it alone. Sarah Faranda brought more than a decade of fertility and women's-health marketing. David Paller, a biomedical engineer, took on business development and the unromantic machinery of fundraising and finance. Marc Chung, fifteen-plus years in life-science consulting, runs clinical development and regulatory. Between them, the leadership team carries north of 75 years in fertility - a useful thing when you are asking the FDA to take you seriously.
Investors noticed. In January 2024, GV - Google's venture arm - led a $14M Series A. A year later, the strategic heavyweights of the fertility world, Gedeon Richter and CooperSurgical, put in another $15M. For a 17-person company, that is a remarkably crowded cap table.
Four co-founders set out to in-license proven IVF medicines for the US market.
Google Ventures anchors the round; CooperSurgical and Gedeon Richter join.
Existing strategic investors double down to expand the reproductive-health pipeline.
Adds OVI-586 and an ovarian-aging program built on Mass General IP.
Lead gonadotropin enters pivotal trial across US fertility centers; completion estimated 2028.
Most early biotechs live or die on a single molecule. Granata Bio spread its bets across four IVF product classes - ovarian stimulation, luteal-phase support, and beyond - so that a stumble in one program does not end the story.
The lead asset. A human menopausal gonadotropin in a pivotal, placebo-controlled Phase III study measuring follicle development, pregnancy and cumulative live birth in IVF cycles.
A hypoglycosylated follicle-stimulating hormone, developed via joint venture with Georgetown Equity Partners and aimed at first-in-human studies.
From the Oviva acquisition. A first-in-class therapeutic designed to extend ovarian function, with potential reach into IVF, menopause and contraception.
Proven medicines used in IVF abroad, brought through US development and commercialization for North American clinics.
The investor list reads like a fertility-industry guest book: GV for the venture credibility, CooperSurgical and Gedeon Richter for the strategic muscle of companies that actually sell into clinics. When the people who know a market best re-up, it tends to mean something.
The April 2025 acquisition of Oviva Therapeutics was the moment Granata Bio stopped being only an in-licensing shop. OVI-586, built on intellectual property from Massachusetts General Hospital, targets ovarian aging itself - the engine room of fertility decline. It is a bigger, riskier idea than importing a known drug. It is also a far bigger prize.
Strip away the molecules and the mission is plain: identify and develop therapies that expand access and improve outcomes. Granata Bio is not trying to be the biggest fertility company. It is trying to be the one that hands a clinician an option that did not exist last year - and makes it reachable for the patient in the chair.
The team describes its culture in three words - productivity, authenticity, and the courage to drive innovation. For a company this lean, those are not poster slogans. They are a staffing strategy.
Return to the exam room where we started. The woman beginning IVF in late 2025 is being offered something her mother's generation could not have been: a shot at a therapy still being proven, from a company built specifically to close the gap she is standing in. If GRACE reads out as hoped around 2028, that option becomes a product. If OVI-586 holds up, the very clock she is racing might one day slow down.
None of it is guaranteed. Phase III trials fail. First-in-class mechanisms humble their believers. But the thing about a 17-person company named after a fertility symbol is that it has already done the part most of the industry would not - it showed up. The medicine cabinet US patients were never offered is, finally, being stocked.